 |
|
|
| |
Year
Established |
1998 |
|
|
| |
Total
Employees |
250 |
|
|
| |
Scientists & Physicians |
186 |
|
|
| |
Facilities |
220,000
square
feet |
|
|
|
|
|
|
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company, with two wholly-owned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib (with AstraZeneca), MEK162 (with Novartis), and danoprevir (with InterMune/Roche) having the potential to begin Phase 3 or pivotal trials by the end of calendar year 2013.
Our Strategy
We are building a fully integrated, commercial-stage biopharmaceutical company that discovers, develops and markets safe and effective small molecule drugs to treat patients afflicted with cancer. We intend to accomplish this through the following strategies:
- Invent targeted small molecule drugs that address critical unmet medical needs for patients fighting cancer.
- Build internal expertise, including a U.S.-based sales force, to develop and commercialize Array products in hematology/oncology.
- Seek partnerships to maximize value for our clinical-stage products being developed outside hematology/oncology.
|
